‒ Two Presentations at ASB M R , including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 regist r ational trial in 2022 ‒ BOSTON and JERUSALEM, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of

‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for osteoporosis and several other molecules now in development by Entera and in collaboration with

Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data Pivotal Phase 3 registration study expected to commence 2022 BOSTON and JERUSALEM, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒   BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday,

‒ Phase 2 EB613 Clinical Trial in Osteoporosi s Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 M eeting with FDA for P lanned P ivotal O ne-year Phase 3 S tudy C omparing C hanges in L umbar S pine BMD in P atients T reated

BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at 06:30am ET.

‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month Biochemical Markers of Bone Formation and Resorption to be Presented ‒ ‒ Positioned to be the First Oral

BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613